3 results match your criteria: "National Hospital Organization (NHO) Kumamoto Saishun Medical Center[Affiliation]"
Use of Upadacitinib to Treat a Severe Flare-Up of Rheumatoid Arthritis During Anti-PD-1 Immune Checkpoint Inhibitor Therapy for Stage IV Squamous Cell Carcinoma of the Lung.
J Clin Med
October 2024
Department of Respiratory Medicine, National Hospital Organization (NHO) Kumamoto Saishun Medical Center, Kohshi 861-1196, Kumamoto, Japan.
Immune checkpoint inhibitor (ICI) therapy is becoming the standard of care for the treatment of advanced non-small-cell lung cancer. However, T-cell activation by ICIs frequently induces a flare-up of preexisting autoimmune diseases such as rheumatoid arthritis (RA). Janus kinase (JAK) inhibitors are increasingly used in the treatment of RA, but they could interfere with the efficacy of ICIs by inhibiting interferon signaling.
View Article and Find Full Text PDFIncidence of and predictive factors for lung cancer in patients with rheumatoid arthritis: A retrospective long-term follow-up study.
Mod Rheumatol
September 2024
Department of Respiratory Medicine, NHO Kumamoto Saishun Medical Center, Kohshi, Kumamoto, Japan.
Article Synopsis
- - The study aimed to assess how common lung cancer is among patients with rheumatoid arthritis (RA) and identify factors that predict its occurrence.
- - Out of 771 RA patients followed for an average of 9.3 years, different lung conditions showed varied lung cancer incidence rates, with CPFE patients at the highest risk (47.8 cases per 1,000 patient-years).
- - Findings suggest that RA patients with smoking history and pulmonary complications, particularly CPFE, should be closely monitored for lung cancer risk.
Impact of combined pulmonary fibrosis and emphysema on lung cancer risk and mortality in rheumatoid arthritis: A multicenter retrospective cohort study.
PLoS One
February 2024
Department of Internal Medicine and Rheumatology, Clinical Research Institute, NHO Kyushu Medical Center, Fukuoka, Japan.
Objective: Combined pulmonary fibrosis and emphysema (CPFE) is a syndrome characterized by the coexistence of emphysema and fibrotic interstitial lung disease (ILD). The aim of this study was to examine the effect of CPFE on lung cancer risk and lung cancer-related mortality in patients with rheumatoid arthritis (RA).
Methods: We conducted a multicenter retrospective cohort study of patients newly diagnosed with lung cancer at five community hospitals between June 2006 and December 2021.